Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT05317819, led by Polaris, and recruiting on the registry. Official title: A Randomised, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma. Planned enrolment is 300 participants (estimated). The study started in 2022-03-14 and primary completion is expected in 2028-09. No results have been posted on ClinicalTrials.gov.